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A B S T R A C T   
Background: Posttraumatic Stress Disorder (PTSD) is a debilitating mental health disorder. Certain drugs, such as 
morphine and nitrous oxide gas (N2O), are administered to individuals who just experienced a traumatic event 
(e.g., soldiers, injured civilians). It is therefore crucial to understand if they incidentally affect PTSD symptom 
development. Furthermore, such observations could pave the way for the development of pharmacological 
prevention strategies of PTSD. 
Methods: In this prospective population-based cohort study (n = 2,070), we examined the relationship between 
morphine or N2O administration during childbirth, and subsequent childbirth-related PTSD symptoms at eight 
weeks postpartum. Pain during labour, prior PTSD symptoms, and birth medical severity were included as 
covariates in the analyses. 
Results: In women who developed PTSD symptoms, N2O administration during childbirth predicted reduced 
PTSD symptom severity (p < .001, small to medium effect size). A similar tendency was observed for morphine, 
but was not significant (p < .065, null to small effect size). Both drugs predicted increased PTSD symptoms when 
combined with severe pain during labour. 
Limitations: This study was observational, thus drug administration was not randomised. Additionally, PTSD 
symptoms were self-reported. 
Conclusions: Peritraumatic N2O administration may reduce subsequent PTSD symptom severity and thus be a 
potential avenue for PTSD secondary prevention. This might also be the case for morphine. However, the role of 
severe peritraumatic pain in context of drug administration deserves further investigation.   
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1. Introduction 
Posttraumatic1 stress disorder (PTSD) is a mental health disorder, 
which may occur after experiencing or witnessing a traumatic event 
(American Psychiatric Association, 2013), and has a lifetime prevalence 
of 3.9% (Koenen et al., 2017). Symptoms include re-experiencing, 
avoidance of trauma-related reminders, alterations in arousal, and 
negative cognitions and mood (American Psychiatric Association, 
2013). They are present at least one month after the traumatic event 
(American Psychiatric Association, 2013) and have a mean duration of 
six years (Kessler et al., 2017). PTSD is comorbid with depression, 
anxiety, and substance abuse disorders (Brady et al., 2012). Even at 
subclinical levels, PTSD symptoms are associated with substantial 
functional impairment (Brancu et al., 2016), distress and suicidal idea-
tion (McLaughlin et al., 2015). While evidence-based treatments for 
PTSD exist (Lewis et al., 2020), preventive interventions are lacking (Qi 
et al., 2016). Yet, PTSD onset is linked to an identifiable and temporally 
defined causative event, making it an ideal candidate for secondary 
prevention approaches (Qi et al., 2016). 
The evidence of successful drug treatments for PTSD is mixed 
(Hoskins et al., 2015). However, when administered during the early 
posttraumatic period, certain drugs are associated with reduced subse-
quent PTSD symptoms (Astill Wright et al. 2019). Preliminary evidence 
suggesting such a protective relationship has, for instance, been reported 
for morphine, a pain relief medication of the opiate family. Two retro-
spective studies found that military personnel had a reduced likelihood 
of developing PTSD if they received morphine within the first hours 
following their brain or limb injuries (Holbrook et al., 2010; Melcer 
et al., 2014). However, one did not find such a relationship (Mion et al., 
2017). Amongst civilians, receiving opiates or elevated morphine dose 
within 48 h following a traumatic injury was also associated with milder 
PTSD symptoms (Bryant et al., 2009; Mouthaan et al., 2015), although 
contradictory results were reported with opiate doses after lung injury 
(Bienvenu et al., 2013). 
Another widely used pain relief is nitrous oxide gas (N2O). Unlike 
morphine, the relationship between N2O inhalation in the early post-
traumatic period and PTSD development has received little attention. 
Yet, compared to medical air, N2O inhalation after an analogue trauma 
significantly sped up the reduction of trauma-related intrusive memories 
(Das et al., 2016), a core symptom of PTSD. Importantly, results sug-
gested that early inhalation of subanesthetic levels of N2O may reduce 
PTSD symptoms while preserving voluntary memory. However, this 
relationship has never been investigated in the context of real-life 
trauma, nor beyond the first posttraumatic week. 
Morphine and N2O are used in a variety of contexts, such as intensive 
care units, labour wards, and in military medicine. Hence, they are 
administered to populations at high risk of PTSD. It is thus critical to 
assess whether these drugs have unsuspected effects on PTSD symptom 
development when administered in the early posttraumatic period. Such 
observations could also be a first step towards secondary pharmaco-
logical prevention of PTSD (Astill Wright et al., 2019; Maccani et al., 
2012). On the contrary, they may reveal that morphine and N2O cause 
iatrogenic harm (Fluegge, 2018). In any case, prospective studies on 
real-life traumas are lacking, especially for N2O. 
The underlying mechanisms of the association between early drug 
administration and PTSD symptom development are not well under-
stood. One hypothesis is that morphine and N2O impact memory 
consolidation, a time-dependent process of stabilisation of memories 
into long-term memory (McGaugh, 2000). During the consolidation 
window, lasting several hours after the event, memories are malleable 
and sensitive to interference (Nader et al., 2000). As PTSD is assumed to 
result from maladaptive memories and excessive fear learning (Pitman, 
1989; van Marle, 2015), drugs disrupting the consolidation of trauma 
memories may prevent PTSD symptom development (Astill Wright 
et al., 2019). Morphine, for instance, impairs learning and reduces fear 
responses when administered after fear conditioning in rodents (e.g., 
McNally and Westbrook, 2003; Szczytkowski-Thomson et al., 2013). 
Similarly, N2O inhalation can impair learning in both rodents (Rabat 
et al., 2004) and humans (Dunlosky et al., 1998). N2O is, inter alia, an 
antagonist of N-methyl D-aspartate receptors (Emmanouil and Quock, 
2007), which are implicated in long-term potentiation (LTP) (Luscher 
and Malenka, 2012). As LTP is one of the hypothesised mechanisms of 
memory consolidation (Nader and Hardt, 2009), N2O is likely to disrupt 
memory consolidation. In terms of memory processes, it is also possible 
that morphine and N2O, if administered very early, interfere with 
encoding. In this case, they could contribute to memory disorganization, 
which is frequently found in patients with PTSD (Brewin, 2018), and 
thus potentially trigger or worsen PTSD symptomatology. 
An alternative explanation of the relationship between early drug 
administration and PTSD symptoms is pain relief. Indeed, morphine and 
N2O reduce peritraumatic pain, a well-known risk factor for PTSD 
(Ayers et al., 2016). Given that the severity of the patients’ medical 
situation may impact pain relief drug administration, peritraumatic pain 
may also reflect the severity of patients’ medical situations. Both the 
severity of the patients’ medical situation and peritraumatic pain are 
thus important to consider within this hypothesis. Importantly, the pain 
hypothesis is challenged by research on rodents, suggesting that 
morphine still reduces fear responses when administered after the end of 
the painful stimuli (e.g., RaiseAbdullahi et al., 2019). So far, few clinical 
studies included pain in their analyses. Even if these tend to support the 
hypothesis of an independent action of morphine on PTSD development 
(Bryant et al., 2009), the lack of data from prospective studies precludes 
firm conclusions. 
The relationship between early drug administration and PTSD 
symptom development has never been studied in the context of child-
birth. Yet, childbirth seems an opportune context: firstly, childbirth- 
related PTSD (C-PTSD) affects four to six per cent of mothers in com-
munity samples, and 18.5% in high-risk samples (e.g., emergency 
caesarean sections (ECS)) (Yildiz et al., 2017). Second, morphine and 
N2O are routinely administered during birth. Third, childbirth is one of 
the most standardised real-life traumas, with a relatively homogeneous 
population and a similar peritraumatic environment (a care setting). 
Finally, since women have medical appointments during pregnancy, it is 
possible to obtain reliable measures of prior PTSD symptoms, a crucial 
risk factor for PTSD (Delahanty and Nugent, 2006). 
To summarise, early morphine and N2O administration might have 
an unexpected preventive effect on PTSD symptom development. 
However, there is a need for more prospective studies, taking the role of 
peritraumatic pain into account. This population-based cohort study 
firstly focused on the relationship between morphine or N2O adminis-
tration during childbirth and C-PTSD symptoms at eight weeks post-
partum. In addition, we explored the role of pain during labour as a 
potential covariate, whilst controlling for prior PTSD symptoms and 
birth medical severity. We hypothesized that receiving morphine or N2O 
during childbirth would predict reduced C- PTSD symptoms. 
2. Method 
2.1. Design and study population 
Data were derived from a large population-based prospective cohort 
study: the Akershus Birth Cohort (ABC). Thus, the results of this study 
stem from secondary analyses. 
The ABC targeted all women scheduled to give birth at Akershus 
University Hospital (Norway), which serves around 350,000 
2 ABC = Akershus Birth Cohort; AIC = Akaike Information Criterion; C-PTSD 
= Childbirth-related PTSD; ECS = Emergency caesarean Section; IES = Impact 
of Event Scale; IRM = Item Response Model; ISS = Injury Severity Score; MINI 
= Mini-International Neuropsychiatric Interview; N2O = Nitrous oxide gas; 
RESI = Robust Effect Size Index; VIF = Variance Inflation Factor. 
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inhabitants. Recruitment took place between November 2008 and April 
2010, during the 17-week pregnancy routine examination. Women were 
eligible to participate if they could complete the questionnaires in 
Norwegian. 
Participants completed questionnaires during pregnancy, at 17 weeks 
and 32 weeks of gestation, and at eight weeks and two years postpartum. 
Medical information relating to the birth was registered in the hospital 
birth record. Participants who gave birth between May 2009 and 
September 2010 completed an additional questionnaire on pain at 48 
hours postpartum. The ABC obtained ethical approval from the Regional 
Committees for Medical and Health Research Ethics (approval number S- 
08013a), and all participants provided written informed consent. Of the 
eligible women, 80% (n = 3,752) agreed to participate and returned the 
first questionnaire. Detailed information on participants and drop out in 
the ABC can be found in Garthus-Niegel et al. (2018). 
In this study, we used data from the 17-weeks of gestation ques-
tionnaires, the eight weeks postpartum questionnaires, and the hospital 
birth record. Out of the 3,752 women who returned the 17-week ques-
tionnaire, we excluded those for which the hospital birth record was not 
available (n = 189). We also excluded women who received pethidine, 
which is an opioid (n = 2), or general anaesthetics (n = 73) during 
childbirth, because these drugs might independently affect PTSD 
symptom development. Women who received opiates other than 
morphine (n = 8) were excluded, too: since data on the type of opiate 
and mode of administration were not available, their inclusion would 
have made interpretation of the results difficult. Finally, we excluded 
women who did not return the questionnaires of interest at eight weeks 
postpartum (n = 1,395), or did not fully complete them (n = 15). Our 
final sample consisted of 2,070 women (Fig. 1). 
2.2. Measures 
2.2.1. Childbirth-related PTSD symptoms 
The 15-item self-rating Impact of Event Scale (IES) (Horowitz et al., 
1979) was used to measure C-PTSD symptoms at eight weeks post-
partum. The IES has been validated in postpartum women (Olde et al., 
2006). Participants were instructed to complete the scale in relation to 
their childbirth. Each item concerns one symptom, with four response 
categories (usually recoded with the following weightings: 0 = not at all, 
1 = rarely, 3 = sometimes, and 5 = often). Sum scores of the overall 
scale can be computed (range 0–75), and scores above 34 indicate 
probable PTSD (Neal et al., 1994). In this study, we took into account the 
ordinal nature of the response scale by using a polytomous Item 
Response Model (IRM) (Hambleton et al., 1991), to estimate a global IES 
Fig. 1. Response and participation rates of the study.  
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score. 
2.2.2. Prior PTSD symptoms 
Prior PTSD symptoms were reported at 17 weeks of pregnancy. 
Women indicated whether they suffered from eight PTSD symptoms 
over the past month, in relation to a dramatic or terrifying event they 
potentially experienced. This PTSD symptom checklist was derived from 
the Mini-International Neuropsychiatric Interview (MINI) (Sheehan 
et al., 1998). Each item was scored 0 (symptom absent) or 1 (symptom 
present); the total scores ranged from 0 (no symptoms) to 8. See Gar-
thus-Niegel et al. (2018) for a detailed description of this scale. In the 
present study, the prior PTSD symptoms score was computed with a 
dichotomous IRM (Hambleton et al., 1991). 
2.2.3. Pain relief administered during childbirth 
Data regarding morphine or N2O administration during childbirth 
was extracted from the hospital birth record. Each drug was treated as a 
dichotomous variable, depending on whether it was used (1) or not (0). 
Both morphine and N2O, if needed, were given during labour. Morphine 
was administered intramuscularly. N2O was given through an inhalation 
mask. Participants were instructed to breathe in the mask as needed, and 
received 30 to 50% N2O. 
2.2.4. Pain during labour 
Pain during labour was measured at 48 hours and eight weeks 
postpartum, with the following question: “How much pain did you feel 
during labour?”. Participants replied using a numerical rating scale from 
0 (“no pain at all”) to 10 (“most intense imaginable pain”), which is a 
valid way of measuring pain intensity (Ferreira-Valente et al., 2011). 
Not all participants completed the questionnaire at 48 hours, but the 
pain ratings from both time points were highly correlated (r = .76, p <
.01) and indicated good test–retest reliability (intraclass correlation =
.88, p < .001). Therefore, due to the larger sample size available at eight 
weeks (2,070 vs 682 participants), we used the eight-weeks assessment. 
2.2.5. Birth medical severity 
Based on hospital birth records, a dichotomous variable was created, 
depending on whether the birth involved the use of forceps, vacuum, 
ended in an ECS (1) or not (0). ECS were considered as such if they were 
planned less than eight hours before delivery. This variable aimed to 
reflect birth medical severity, just as scores like the Injury Severity Score 
(ISS) reflect the severity of patients’ medical situations in other pop-
ulations (Holbrook et al., 2010). To our knowledge, a validated equiv-
alent of the ISS does not exist in obstetrics. Thus, we used operative birth 
as a proxy for medical severity, as it indicates an urgency for the birth to 
occur quickly. Although they are operative, planned caesarean sections 
were coded “0”, as they do not reflect medical emergency during birth. 
Besides, planned caesarean sections are not associated with as poor 
maternal adjustment outcomes as ECS (Alderdice et al., 2019), nor with 
comparable PTSD prevalence (Orovou et al., 2020). 
2.2.6. Parity 
Parity was reported by participants at 17 weeks of pregnancy, and 
recoded as 0 for nulliparous and as 1 for parous. 
2.2.7. Sociodemographic characteristics 
Education, marital status, and age at the time of birth were retrieved 
from the hospital birth record. Education had three categories, reflecting 
the highest achieved degree: elementary school (0), high school (1), and 
higher degree (2). Marital status was recoded into a dichotomous vari-
able, distinguishing married/cohabiting women (1) versus singles (0). 
2.3. Data analysis 
2.3.1. Sample description 
Descriptive analyses for the sociodemographic and obstetric 
variables, as well as PTSD-related scores were carried out for the total 
study sample. For C-PTSD symptoms, prior PTSD symptoms, pain during 
labour, and birth medical severity (the main study variables of interest), 
the sample was divided into four groups, based on drug administration 
during labour. Women either received no pain relief drug, morphine, 
N2O, or a combination of morphine and N2O. For all the analyses, we 
checked if the appropriate statistical assumptions were met and, if not, 
non-parametric tests were used. Group differences were investigated 
through chi-square analyses (categorical variables) or Kruskal-Wallis 
tests (continuous variables). Post-hoc comparisons with a Bonferroni 
correction were used to assess group differences in pain during labour, 
across the four drug-administration groups. 
Given that ageing may increase the risk of obstetrical complication 
(Schummers et al., 2018) and thus affect drug administration, a post-hoc 
one-way between-subjects ANOVA was carried out to evaluate if age 
differed across the drug-administration groups. Group comparisons with 
a Bonferroni correction were used to assess drug group differences in 
age. Similarly, an independent sample t-test was conducted to compare 
age depending on birth medical severity. IBM SPSS 24 was used for all 
analyses in relation with sample description (Tables 1 and 2). 
2.3.2. Prior PTSD and C-PTSD scores 
For the total scores of both the IES and MINI-based prior PTSD 
symptom checklist, we took into account the ordinal nature of the 
response scale by using an Item Response Model (IRM). IRM are a class 
of statistical models designed to model categorical responses using 
probabilities (Hambleton et al., 1991). These models allow proper 
quantification of subject responses without a priori assuming equidis-
tant response categories. By contrast with factor techniques, they 
explicitly incorporate person parameters (i.e., locations on some latent 
dimension) that directly model individual specificities in the response 
process, which is especially relevant for patient-reported outcomes (see 
Supplementary material, section I, “IRM and calculation of symptom 
scores” for details on scores computation). 
2.3.3. Generalized linear regression models 
A series of generalized linear regression models were fitted to explain 
IES scores at eight weeks from our main predictors: prior PTSD symp-
toms, pain during labour, birth medical severity, and morphine or N2O 
administration. The latter were coded as present or absent because we 
wanted to quantify drug effects rather than group differences. An 
advantage of this coding is its ability to reveal more fine-grained 
interaction effects, in particular a potential interaction between both 
drugs, for women who received a combination of morphine and N2O. 
A zero-inflated Tweedie compound Poisson model (Zhang, 2013) 
was used, including two components: a logistic part discriminating be-
tween the zero and non-zero scores (absence vs. presence of symptoms), 
and a Tweedie compound Poisson model accounting for the non-null 
score variance (i.e., modelling stress intensity) (see Supplementary 
material, section II, “Zero-inflated Tweedie compound Poisson model” 
for details on the reasoning behind this model choice). Note that two sets 
of regression coefficients result from this analysis, one for each part of 
the model. All analyses were performed using the ‘cplm’ R package 
(Zhang, 2013). 
A model comparison approach, where models of varying complexity 
are considered in turn, was adopted. In our modelling strategy, for sta-
tistical but also interpretability reasons, no interaction effect was 
included without adding the corresponding main effects or lower order 
interactions. The four following structures have been fitted on both zero- 
inflated and Tweedie components: i) a full model including all variables 
and their interactions up to second order (third order interactions were 
not included to avoid zero counts cells); ii) a reduced model (reduced 
model 1) including all effects and first order interactions; iii) a reduced 
model (reduced model 2) including only main effects; iv) a restricted 
model where only significant predictors from the full model were 
included. Combining these hypothetical structures on both parts of the 
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model resulted in a set of 16 models that were compared using the 
Akaike Information Criterion (AIC) (Akaike, 1973). Note that AIC model 
selection is relatively robust to collinearity, provided that the sample 
size is large enough (i.e. N ≥ 2000) (Brewer et al., 2016). Robust Effect 
Size Indices (RESI) (Vandekar et al., 2020) were calculated for each 
coefficient within the retained model. 
3. Results 
3.1. Characteristics of the study sample 
In our sample, mean maternal age at birth was 31.33 years (SD = 4.6) 
(Table 1). Most participants had obtained a higher educational degree. A 
majority of women received N2O during birth, while a minority received 
morphine (Table 1). The mean number of PTSD symptoms before 
childbirth was low (M = 0.25; SD = 0.76). At eight weeks postpartum, 
according to the IES original weighted scoring, 1.9% of our sample had 
probable C-PTSD (Table 1). 
Table 2 reports each of the main study variables of interest, ac-
cording to the drugs received by women during childbirth. Groups 
differed in terms of pain during labour (H(3) = 137.08, p < .001). A post- 
hoc pairwise comparison revealed that women receiving no pain relief 
reported significantly less pain than those who received N2O (p < .001) 
or both morphine and N2O (p < .01) (Table 2). Groups also significantly 
differed in terms of age (F(3, 2066) = 3.124, p < .05). A post-hoc 
pairwise comparison showed that the only difference was that women 
who received no pain relief (M = 31.68, SD = 4.54) were slightly older 
than those who received N2O (M = 31.09, SD = 4.6) (p < .05). However, 
since the age difference was only seven months, it is unlikely to have led 
to a substantial increase of obstetrical complications. Women who 
received morphine (M = 31.4, SD = 3.8) or both morphine and N2O (M 
= 32.26, SD = 5.05) did not differ from the others. Furthermore, women 
whose birth involved vacuum, forceps, or ECS (M = 31.4, SD = 4.46) 
were similar in age compared to the others (M = 31.32, SD = 4.32); t 
(2068) = 0.302, p = .762. Thus, age did not appear as a relevant variable 
and was not included in our model. 
3.2. Associations with C-PTSD scores 
The best model retained included only main effects on the zero 
inflation model, and main and first order interactions in the Tweedie 
regression model (see Supplementary material, section III, “Model 
comparison and selection” for the AIC of each model). Corresponding 
model coefficients are displayed in Table 3, along with RESI (Vandekar 
et al., 2020) and Variance Inflation Factors (VIF). Although a strong 
collinearity (VIF > 10) is apparent for six terms out of 20, the use of AIC 
model selection and the RESI allows to identify relevant predictors. 
The zero inflation model (Table 3.a) showed that few prior PTSD 
symptoms, mild pain during labour, and low birth medical severity 
(neither vacuum nor forceps nor ECS) were all significant predictors of a 
zero response to IES, thus reinforcing the relevance of these covariates in 
our analyses. However, only pain was close to a noticeable effect size (S 
= 0.0978). 
Coefficients in the Tweedie regression model (Table 3.b) showed that 
N2O inhalation during childbirth decreased the IES score (β = -0.4062, p 
< .001), i.e., reduced C-PTSD symptom severity. The effect size was 
small to medium (S = 0.1121). A similar tendency was apparent for 
morphine, although the corresponding coefficient was not significant (β 
= -0.8454, p = .064) and the effect size was null to small (S = 0.0290) 
(Table 3.b). Significant first order interactions of both N2O and 
morphine with pain during labour were found, with positive co-
efficients. The effects sizes were respectively small to medium (S =
0.1179) and null to small (S = 0.0326). This result suggests that women 
who received N2O during birth were likely to develop more severe C- 
PTSD symptoms if the pain level was high, and log-proportionally to 
pain level. The same pattern of opposite effects, with pain as a moder-
ator, was observed for morphine, although the main protective effect of 
morphine did not reach significance (Table 3.b). Scatter plots of pain 
severity and IES scores in the four drug-administration groups can be 
Table 1 
Characteristics of the study sample (n = 2,070).  
Sample characteristics (time point measured;range) Frequency (%) Mean (SD) 
Sociodemographic characteristics   
Age (at time of childbirth;18–45)  31.33 (4.6) 
Education (at time of childbirth)   
Elementary 62 (3a)  
High school 579 (28a)  
Higher degree 1362 (65.8a)  
Marital status (at time of childbirth)   
Married or cohabiting 2009 (97.1a)  
Single 46 (2.2a)  
Obstetrical factors   
Parity (pregnancy week 17)   
Nulliparous 1009 (48.7)  
Parous 1061 (51.3)  
Pain during labour (8 weeks postpartum;0–10)   
Pain relief (at time of childbirth)  7.73 (2.4) 
No pain relief 796 (38.5)  
Morphine 17 (0.8)  
N2O 1225 (59.2)  
Morphine and N2O 32 (1.5)  
Birth medical severity (forceps, vacuum, ECS) 384 (18.6)  
PTSD symptoms   
Prior PTSD symptoms (pregnancy week 17)   
Raw score (0–8)  0.25 (0.76) 
IRM scoreb (-0.25–3.19)  -0.04 (0.54) 
C-PTSD symptoms (8 weeks postpartum)   
Score (0–65)  6.82 (8.11) 
Score>34, probable C-PTSDc 39 (1.9)  
IRM scoreb (0–4.97)  1.28 (0.91) 
Note. N2O = Nitrous oxide gas; ECS = Emergency caesarean section; IRM = Item 
Response Model; C-PTSD= Childbirth-related PTSD 
a Total of % does not equal 100 because of missing values (n = 2,003 for 
education and n = 2,055 for marital status). 
b Scores computed using an IRM. It is these scores that are used in our analysis. 
c Scores derived from the original weighted IES scoring. Reported for 
descriptive purposes only. 
Table 2 











































3 (17.65) 239 
(19.51) 











1.6 (0.8) .09b 
Note. N2O = Nitrous oxide gas; IRM = Item Response Model; ECS = Emergency 
caesarean section; C-PTSD = Childbirth-related PTSD 
a Scores computed using an IRM. 
b Statistical significance was computed via Kruskal-Wallis test. 
c Statistical significance was computed via Chi-square test.* p < .05** p <
.01*** p < .001 
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found in Fig. 2. As illustrated by Fig. 3, the administration of morphine, 
N2O or both was associated with more severe C-PTSD symptoms from a 
pain rating of about 9 out of 10. Note that morphine and N2O admin-
istration did not statistically interact (p = .79). 
In view of the moderating role played by N2O in the final model, its 
impact was further investigated by performing two mediation analyses 
on the Tweedie part of the model, using the mediation package in R 
(Tingley et al., 2014). No significant mediating effect of N2O in the 
pain/C-PTSD relationship, nor of pain in the N2O/C-PTSD relationship, 
was found. 
3.3. Discussion 
In this large population-based cohort study, we examined the pro-
spective relationship between morphine or N2O administration during a 
real-life traumatic event, and PTSD symptoms eight weeks later. Pur-
suant to our hypothesis, N2O administration during childbirth predicted 
milder C-PTSD symptoms when controlling for birth medical severity, 
prior PTSD symptoms, and pain during labour. Although not statistically 
significant (p < .065), a similar association was observed with 
morphine. We believe this latter result warrants attention given the low 
p-value, the number of studies reporting a protective effect of morphine, 
and the small number of women who received morphine in our sample 
(n = 49/2,070). 
The second aim of this study was to explore the role of peritraumatic 
pain as a covariate. The significant interaction between drugs and per-
itraumatic pain indicates that women who received analgesics and re-
ported intense pain during labour (⩾ 9/10) had more severe C-PTSD 
symptoms, thus suggesting that pain does play a role. However, unlike 
N2O, it should be noted that the effect size of the interaction between 
pain and morphine was null-small – which might be due to low power. 
Importantly, the above-mentioned results only apply to mothers 
reporting some C-PTSD symptoms, as neither morphine nor N2O 
administration predicted the absence of C-PTSD symptoms. 
3.4. Underlying mechanisms 
Although our study remains observational, several elements could 
contribute to the debate on mechanisms underlying the relationship 
between early drug administration and PTSD. 
3.4.1. Memory consolidation hypothesis 
A priori, a drug can only disrupt memory consolidation if it is 
administered and active during the early posttraumatic period, within 
the memory consolidation window. In our study, analgesics were 
administered during labour. Importantly, childbirth can be composed of 
several traumatic experiences (e.g., unexpected induction of labour, an 
ECS). Thus, some mothers may have received pain relief during the 
posttraumatic period, whilst others may have received them during the 
pretraumatic period, i.e. outside of the memory consolidation window. 
This may explain why morphine was not significantly associated with 
milder C-PTSD symptoms although, since it has a half-life of a couple of 
hours (Berkowitz, 1976), the drug may still have been active in the 
posttraumatic period. This is less likely for N2O, which has a half-life of 
three minutes (Hale, 1999). Finally, given that the drugs were some-
times given during the pretraumatic period, they may have, in addition 
to disrupting memory consolidation, affected stress response (Mouth-
aan et al., 2015). 
3.4.2. Pain hypothesis 
In our study, N2O predicted reduced C-PTSD symptoms, even when 
controlling for pain. Furthermore, pain did not predict C-PTSD symptom 
intensity, although low pain scores predicted their absence. Besides, the 
pain scores of women who received N2O or a combination of morphine 
and N2O were significantly higher than those of the control group, while 
women who received morphine had a score comparable to that of the 
Table 3 
Estimated coefficients on the Zero Inflated Tweedie Compound Poisson model of IES.  
(a) Zero inflation logistic model  
Estimatea Std. Error z value Pr(>|z|) RESIb VIF 
(Intercept) -0.6147 0.1692 -3.6326 0.0003*** 0.0788  
Prior PTSD -0.5374 0.1348 -3.9876 0.0001*** 0.0833 1.0030 
Pain -0.1030 0.0229 -4.5054 0.0000*** 0.0978 1.1175 
Birth Medical Severity -0.6798 0.1677 -4.0544 0.0001*** 0.0861 1.0025 
N2O 0.1314 0.1219 1.0781 0.2810 0.0080 1.1165 
Morphine -0.2916 0.4175 -0.6984 0.4849 0.0000 1.0035  
(b) Tweedie regression model  
Estimatea Std. Error z value Pr (>|z|) RESIb VIF 
(Intercept) 0.4168 0.0469 8.8948 0.0000*** 0.2111  
Prior PTSD 0.0785 0.0521 1.5067 0.1319 0.0196 7.5925 
Pain -0.0004 0.0062 -0.0594 0.9527 0.0000 1.9691 
Birth Medical Severity 0.0305 0.0917 0.3325 0.7395 0.0000 12.7208 
N2O -0.4062 0.0841 -4.8291 0.0000*** 0.1121 15.4729 
Morphine -0.8454 0.4568 -1.8507 0.0642 0.0290 41.0325 
Prior PTSD x Pain 0.0072 0.0070 1.0286 0.3037 0.0000 8.8915 
Prior PTSD x Birth medical severity -0.0306 0.0451 -0.6776 0.4980 0.0000 1.2940 
Prior PTSD x N2O -0.0402 0.0407 -0.9872 0.3236 0.0000 2.6150 
Prior PTSD x Morphine -0.0637 0.1210 -0.5260 0.5989 0.0000 1.2258 
Pain x Birth medical severity 0.0217 0.0119 1.8258 0.0679 0.0373 15.2262 
Pain x N2O 0.0514 0.0101 5.0820 0.0000*** 0.1179 17.5108 
Pain x Morphine 0.0999 0.0508 1.9655 0.0494* 0.0326 39.9776 
Birth medical severity x N2O -0.0580 0.0586 -0.9901 0.3221 0.0000 3.4923 
Birth medical severity x Morphine -0.0065 0.1575 -0.0411 0.9672 0.0000 1.3901 
N2O x Morphine 0.0390 0.1462 0.2668 0.7896 0.0000 3.2786 
Dispersion parameter : 0.19617 
Index parameter : 1.8681 
Note. RESI = Robust Effect Size Index; VIF = Variance Inflation Factor; N2O = Nitrous oxide gas. 
a Estimates represent unstandardized β values. 
b Interpretation of Robust Effect Sizes: [0;0.1]: None-Small,]0.10;0.25]: Small-Medium,]0.25;0.4]: Medium-Large (Vandekar et al., 2020). The RESI directly control 
for collinearity by using the parameter information matrix as its main metric (see Vandekar et al. (2020), formula 16): when covariances are high, parameter variances 
are high, and the RESI is low, such that effects with at least small-medium effect sizes (0.10 < S < 0.25) can be confidently interpreted*p < .05**p < .01***p < .001 
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control group. It does not appear that women who received analgesics 
thereby had a less painful experience than those who did not. This is 
probably explained by the fact that it was the pain intensity that led 
women to ask for pain relief. Besides, unless women reported highly 
intense pain, N2O inhalation remained protective. Additionally, the 
mediation analysis did not show that the relationship between N2O and 
C-PTSD symptoms severity was mediated by pain. Overall, these ele-
ments are not in favour of the pain hypothesis. 
3.4.3. Non-pharmacological mechanisms 
Aside from memory consolidation disruption or pain reduction, the 
observed association with PTSD symptoms could be due to indirect 
mechanisms. Firstly, the use of analgesics may enhance women’s sense 
of control, or contribute to a sense of support from the staff, which both 
protect against C-PTSD (Ayers et al., 2016; Czarnocka and Slade, 2000). 
N2O benefits could also come from its mode of administration, as 
focusing on breathing may help to relax (Richardson et al., 2019). 
Finally, all these non-pharmacological aspects could contribute to a 
reduction in PTSD symptoms through improved overall birth experience 
(Garthus-Niegel et al., 2014). They may also explain why N2O and 
morphine both predicted more severe C-PTSD symptoms when com-
bined with intense labour pain: since perceiving the midwife as in 
control of the situation is a protective factor for C-PTSD (De Schepper 
et al., 2016), inefficient pain relief may give the impression that the staff 
is powerless. 
3.5. Study limitations 
Despite the prospective, population-based design, the large sample 
size and the inclusion of important confounding variables, this study has 
several limitations. The first, which is inherent in observational clinical 
studies, is that drug administration was not randomised. While this is for 
obvious ethical and medical reasons, it may lead to biases. For that same 
reason, our sample included only a few women who received morphine, 
and thus we may have lacked statistical power for this drug. 
Another limitation of our study concerns the type of measurement 
used. PTSD symptoms, whether pre-existing or childbirth-related, were 
self-reported. As for pain, it was measured at eight weeks postpartum, 
and thus may reflect pain memory, despite a strong correlation between 
pain at 48 hours and eight weeks postpartum. Additionally, since these 
analyses were not designed at the time of data collection, we do not have 
specific information on the intensity of pain relief provided by morphine 
and N2O. Our measurement of pain thus remains a global indicator, 
which limits the mechanistic interpretations and notably the interpre-
tation of the mediation analyses. 
Furthermore, we acknowledge that using ECS, forceps, or vacuum as 
a proxy for birth medical severity is also a limitation. While it was 
necessary to take into account the severity of the obstetrical situation at 
the time of delivery, use of a validated index, had it been available, 
would have been preferable. 
As shown by the VIF in Table 3, the important collinearity detected 
Fig. 2. Marginal model curves of the relationship between pain rating and IES score in the four pain relief groups, based on the full Tweedie regression model. 
Note. IES = Impact of Event Scale; N2O = Nitrous oxide gas. 
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for several terms of the Tweedie regression may also limit the inter-
pretation of results, although this collinearity is taken into account in the 
RESI computation. 
Finally, despite our exclusion criteria, other drugs may have been 
given during childbirth and thus influenced PTSD symptom develop-
ment. Oxytocin and benzodiazepines, for example, may affect PTSD 
development if administered following the traumatic event (Frijling, 
2017; Guina et al., 2015), although the evidence is mixed (Astill Wright 
et al., 2019; McGhee et al., 2009). 
3.6. Implications and future directions 
We believe that our results suggest that both N2O and morphine 
merit further investigation about their use in the prevention of PTSD 
symptoms development. However, while most of the published studies 
are naturalistic, research would benefit from randomised controlled 
trials. Even if these are difficult to carry out in a clinical context, the 
trauma film paradigm seems to offer a good alternative for laboratory 
studies (James et al., 2016). 
Future research should focus on the dose-response relationship be-
tween administered drugs and PTSD symptom development. Indeed, the 
effects of N2O or morphine on memory (Good and Westbrook, 1995; 
Rabat et al., 2004) or PTSD (Bryant et al., 2009) may be dose-dependent. 
In our study, for instance, morphine dose may not have been sufficient to 
significantly affect PTSD symptoms. With a view to developing pre-
ventive interventions, greater clarity on this issue seems essential. In this 
respect, while morphine can be addictive and have psychotropic effects, 
N2O has the advantage of having a short half-life, and moderate side 
effects (Likis et al., 2014). Besides, it seems to preserve the memory of 
the traumatic event (Das et al., 2016), which is a key aspect of the ethical 
debate on pharmacological prevention of PTSD (Jain et al., 2011). 
Overall, its use is considered safe and minimally invasive (Zafirova et al., 
2018). However, its toxicity is still debated (Fluegge, 2018), and it could 
increase intrusions frequency in dissociated individuals (Das et al., 
2016). Furthermore, while many studies suggest that timing is key (e.g., 
Bryant et al., 2009; RaiseAbdullahi et al., 2019), it has not been sys-
tematically investigated either. 
Among injured or suffering populations, future studies should take 
into account the effects of anaesthesia provided during the peritraumatic 
period. Indeed, anaesthesia procedures may involve not only other drugs 
with singular effects on pain or memory, but also additional (locally 
administered) opioids and opiates. Thus, anaesthesia represents another 
gateway for drugs to enter the body, and its relationship with PTSD 
development remains unclear (Hernandez-Martinez et al., 2020; Lopez 
et al., 2017). 
Furthermore, the protective effect of N2O in the absence of severe 
pain suggests that it would be relevant to examine the preventive po-
tential of analgesics for uninjured victims of traumatic events such as 
witnesses of assaults. On the contrary, since morphine and N2O are 
commonly used to relieve injured patients, it would be important to 
clarify whether their administration actually worsens the severity of 
subsequent PTSD symptoms in those in extreme pain. 
4. Conclusion 
In this study, N2O was associated with reduced C-PTSD symptoms 
when inhaled during the peritraumatic period. Although not significant, 
a similar trend was observed for morphine. Conversely, higher levels of 
pain predicted more severe C-PTSD symptoms in women who received 
morphine or N2O. These results may be of interest to health pro-
fessionals routinely using these two drugs in populations at risk of 
developing PTSD, by providing information on the associations between 
pain relief and mental health. Furthermore, they open up exciting 
prospects for research on N2O as a potential pharmacological agent for 
PTSD prevention. 
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Fig. 3. Relationship between pain and IES score for pain ratings above 7 (on a 
scale from 0-10), as predicted by the full Tweedie regression model for each 
pain relief group. Vertical lines correspond to thresholds for which drugs are 
associated with more severe C-PTSD symptoms. 
Note. IES = Impact of Event Scale; N2O = Nitrous oxide gas. 
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